Compare prices and buy SLU-PP-332 from 21 research peptide vendors - also called suppliers or sources. Updated daily.
SLU-PP-332 (CAS 303760-60-3) is a small-molecule pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma. In mice it activates the ERR transcriptional program driving mitochondrial biogenesis, fatty-acid oxidation, and oxidative muscle fiber-type conversion, pathways that overlap substantially with those induced by endurance exercise. Not a peptide, but catalogued alongside mitochondrial peptides by commercial-intent overlap. Studied preclinically in rodent models of obesity, heart failure, and metabolic syndrome.
For research purposes only. Not medical advice.
SLU-PP-332 is a small molecule, not a peptide. An acyl hydrazone, 4-hydroxy-N'-(naphthalen-2-ylmethylidene)benzohydrazide (C18H14N2O2, CAS 303760-60-3), it is catalogued here alongside the mitochondrial peptides because of commercial overlap, not chemical kinship.
Its targets are the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, orphan nuclear receptors that bind no endogenous estrogen and are constitutively active. Together with the coactivator PGC-1alpha they drive the genes for mitochondrial biogenesis, oxidative phosphorylation and fatty-acid oxidation, the same transcriptional program endurance training induces in skeletal muscle.
ERRalpha had been considered an intractable agonist target, with a collapsed ligand-binding pocket. Thomas Burris and colleagues reached it by structure-based design, optimizing the ERRbeta/gamma-selective agonist GSK4716 with a naphthalene group designed to contact a phenylalanine residue present in ERRalpha where the other two isoforms carry an alanine. That gained 50-fold ERRalpha potency, to an EC50 of 98 nM, with weaker activity at ERRbeta and ERRgamma.
This is a transcriptional lever, distinct from 5-Amino-1MQ, which inhibits an enzyme, from MOTS-c, which signals through AMPK, and from SS-31, which binds cardiolipin in the inner mitochondrial membrane. The comparison is mechanistic, not a ranking.
The founding paper is Billon and colleagues in ACS Chemical Biology, 2023. Sedentary mice given SLU-PP-332 showed increased mitochondrial DNA content, more oxidative type IIa muscle fibers, and ran roughly 70% longer and 45% further than vehicle-treated mice on a treadmill-to-exhaustion test. Genetic knockouts confirmed the effect ran through ERRalpha.
Three follow-ups extended it to disease models. In the Journal of Pharmacology and Experimental Therapeutics in 2024, the same group reported increased energy expenditure and fatty-acid oxidation, decreased fat mass and improved insulin sensitivity in diet-induced obese and ob/ob mice. In Circulation in 2024, Xu and colleagues found that SLU-PP-332 and the related compound SLU-PP-915 improved ejection fraction, reduced fibrosis and increased survival in pressure-overload heart failure, with ERRgamma as the mediator. In the American Journal of Pathology in 2023, Wang and colleagues reported that eight weeks of treatment reversed age-related albuminuria, podocyte loss and mitochondrial dysfunction in 21-month-old mice.
The founding paper compared drug with running on two acute aerobic exercise genes in mouse gastrocnemius muscle, one hour after treatment. SLU-PP-332 induced Ddit4 about 3-fold in sedentary mice, against about 6-fold in mice that actually ran, and the two together were additive at roughly 11-fold. On the second gene, Slc25a25, drug and exercise each produced about an 11-fold increase, and the paper reads the two as similar in magnitude and duration. Both effects were gone by three hours. The gap is breadth rather than magnitude: a 2026 review in Trends in Endocrinology and Metabolism argues that exercise acts through vascular, autonomic, inflammatory and exerkine pathways no single receptor agonist reproduces.
All of the above is cell-culture and rodent work. There is no published human study of SLU-PP-332. ClinicalTrials.gov returns no registered study of it, and Drugs@FDA no approved product containing it, both read on October 21, 2026. Because it is a small molecule rather than a peptide, it also sits outside the compounding proceedings that reshaped much of this catalog: it appears on neither table of the FDA's Category 2 bulk drug substances page and on neither the 503A nor the 503B nomination category list, all read on October 21, 2026, and it was not on the agenda of the July 2026 Pharmacy Compounding Advisory Committee meeting that took up BPC-157 and MOTS-c.
In sport it is prohibited, and named from January 1, 2027. The World Anti-Doping Agency's 2027 Prohibited List adds SLU-PP-332 and the related SLU-PP-915 as examples of metabolic modulators acting particularly on oxidative metabolism. The 2026 list names no ERR agonist, so until then it is caught by S0, which prohibits at all times any substance with no current approval by any governmental health authority. Two anti-doping laboratories published in-vitro metabolite maps for it in 2026, in Rapid Communications in Mass Spectrometry and Drug Testing and Analysis, which is the step that precedes routine screening.
Vendor titles abbreviate the name aggressively: "SLU-PP-332" is standard, with "SLU-PP332", "SLUPP" and bare "SLU" appearing in product slugs and URLs. The prefix records where it was made, at Saint Louis University. PubChem also carries the developer code SR9861.
Oral formats appear in its listings (capsules, tablets and a dropper alongside milligram vials), and that is worth reading against the pharmacology. Every rodent study above dosed SLU-PP-332 by intraperitoneal injection, and its developers state plainly that the compound lacks oral bioavailability. That limitation is why they went on to build SLU-PP-915, a chemically distinct boronic-acid pan-ERR agonist reported in 2026 to retain exercise-mimetic activity when given by mouth. That oral activity belongs to SLU-PP-915, not to SLU-PP-332.
PeptideScouter indexes SLU-PP-332 vials per milligram and verifies identity against its molecular formula.
No. It is a small molecule, an acyl hydrazone with the formula C18H14N2O2 and a molecular weight of about 290. Peptides are chains of amino acids. It is catalogued on PeptideScouter because research vendors sell it beside mitochondrial and metabolic peptides, although it is chemically unrelated to them. PubChem lists the published CAS number 303760-60-3 for the neutral compound rather than a salt, so a stated milligram figure needs no free-base adjustment.
ERRalpha, ERRbeta and ERRgamma are orphan nuclear receptors that share structural homology with the estrogen receptors but bind no endogenous estrogen. They are constitutively active transcription factors, and with the coactivator PGC-1alpha they control genes for mitochondrial biogenesis, oxidative phosphorylation and fatty-acid oxidation. In mice, SLU-PP-332 increased mitochondrial DNA content and oxidative type IIa muscle fibers in skeletal muscle. Its measured potency is 98 nM at ERRalpha, 230 nM at ERRbeta and 430 nM at ERRgamma, making it a pan-agonist with a modest ERRalpha preference.
No. The published evidence is cell-culture and rodent work, beginning with a 2023 ACS Chemical Biology paper from Thomas Burris and colleagues and extending to mouse models of obesity, heart failure and kidney aging. There is no published human study of SLU-PP-332, and ClinicalTrials.gov had no registered study of it when read in October 2026. A 2025 pilot study treated muscle cells taken from human biopsies with the compound in culture, which is laboratory work rather than a human trial. No approved product in Drugs@FDA contains it.
Its developers report that it is not. Every rodent study of SLU-PP-332 administered it by intraperitoneal injection, and the group that discovered it states that the compound lacks oral bioavailability. That limitation is the reason they developed SLU-PP-915, a chemically distinct boronic-acid pan-ERR agonist reported in 2026 to retain exercise-mimetic activity in mice when given by mouth. Research vendors sell SLU-PP-332 in capsule, tablet and oral dropper formats as well as milligram vials, but the oral activity reported in 2026 belongs to SLU-PP-915, a different molecule, which PeptideScouter indexes separately.
Because a per-milligram price is computed only for vials sized in milligrams. SLU-PP-332 is sold as capsules, tablets and a liquid dropper as well as milligram vials, and those non-vial formats are indexed without a per-milligram figure, so the per-milligram comparisons on this page describe vials only.
Yes. The World Anti-Doping Agency's 2027 Prohibited List, in force from January 1, 2027, names SLU-PP-332 and the related SLU-PP-915 as examples of metabolic modulators acting particularly on oxidative metabolism. The 2026 list names no ERR agonist, so until the 2027 list takes effect SLU-PP-332 is covered by section S0, which prohibits at all times any substance with no current approval by any governmental health authority for human therapeutic use. Two anti-doping laboratories published in-vitro metabolite maps for the compound in 2026, in Rapid Communications in Mass Spectrometry and in Drug Testing and Analysis, which is the step that precedes routine screening.
SLU-PP-332 is sold by 21 research peptide vendors indexed on PeptideScouter, with 37 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
17 of the 21 indexed vendors currently have SLU-PP-332 in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Glacier Aminos currently lists SLU-PP-332 at $6.70/mg, the lowest listed price across 21 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $6.03/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 21 vendors listing SLU-PP-332 publish a PeptideScouter code, worth 5% to 15% off. Applied, the lowest effective price falls from $6.70/mg listed to $6.03/mg at Glacier Aminos. Each vendor's code is shown beside its price in the table above.
SLU-PP-332 ranges from $6.70/mg to $23.00/mg across 37 listings from 21 research peptide vendors, normalized to USD per milligram and refreshed daily.
21 research peptide vendors currently list SLU-PP-332 on PeptideScouter, with 17 in stock right now. We track 37 listings across size and kit variants.
SLU-PP-332's CAS Registry Number is 303760-60-3.
